Astellas secured an exclusive option to license global rights to an AviadoBio gene therapy in development as a one-time treatment for a certain type of frontotemporal dementia. A Phase 1/2 test of the AviadoBio gene therapy is ongoing.
Unlike Alzheimer's disease, which is characterized primarily by memory difficulties, but generally not major changes to personality or language, Frontotemporal dementia strikes at the core of what makes us who we are. Fortunately, there are several ongoing clinical trials addressing this disease.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.